RxDoctor Payments Data

Faris Fadheel, MD

Neurology · Evansville, INNPI 1205836608

Payments from drug & device makers

$3,758in general payments, 2019–2025

Across 288 payments — averaging $13.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$397
  • Biogen$333
  • AbbVie$309
  • Sunovion Pharmaceuticals Inc.$161
  • MDD US Operations, LLC$153
  • EMD Serono, Inc.$140
  • plus $2K from 39 others

What the payments were for

  • Speaking & faculty fees$882%
  • Food & beverage$3,60396%
  • Education$672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,758 in reported general payments places this provider in the 55th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$304,389
Medicare patients
663
Services billed
17,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin14$167,494
VumerityDiroximel Fumarate18$153,982
Plegridy PenPeginterferon Beta-1a14$115,780
CopaxoneGlatiramer Acetate17$96,325
Glatiramer Acetate46$58,174
Aimovig AutoinjectorErenumab-Aooe47$34,599
NeuproRotigotine15$23,190
NourianzIstradefylline12$22,258
QuliptaAtogepant17$18,031
Pyridostigmine Bromide ErPyridostigmine Bromide32$15,983
Memantine Hcl484$13,407
Mycophenolate Mofetil26$12,462
Rufinamide13$10,836
Pyridostigmine Bromide49$8,364
Carbidopa-LevodopaCarbidopa/Levodopa264$8,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$140$167,49414 claims
BiogenVumerity$333$153,98218 claims
Teva Pharmaceuticals USA, Inc.Copaxone$61$96,32517 claims
UCB, Inc.Neupro$126$23,19015 claims
Kyowa Kirin, Inc.Nourianz$31$22,25812 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$32$20,82675 claims
AbbVieQulipta$309$18,03117 claims
Upsher-smith Laboratories LLCTopiramate$34$1,688106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 308 neurology providers in Indiana.

Other neurology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →